Payment overview · 2025
General Payments
$44,509.34
48 reported records · 6 companies
Healthcare provider profile · identity verified
Robert J Dobrzynski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · PROVIDENCE, RI · NPI 1598863599
Verified facts
What the public records show
CMS Open Payments records show Robert J Dobrzynski, M.D. received $44,509.34 in general payments during 2025 across 48 reported records.
Novo Nordisk Inc accounted for 67.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 516 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 1203 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30,143.42 | 67.7% | 24 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14,116.10 | 31.7% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.60 | 0.3% | 8 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 0.1% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $41.02 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.70 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,638.44 | 9 |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,639.00 | 4 |
| Travel and Lodging | $2,486.69 | 12 |
| Food and Beverage | $1,702.71 | 22 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27,912.49 | 21 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $14,116.10 | 12 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $14,116.10 | 12 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $141.60 | 8 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 1203 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 516 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
516 | 113 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
1203 | 183 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
100 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2376 | 523 |
| Ozempic | Semaglutide | 1203 | 183 |
| Glimepiride | Glimepiride | 1122 | 287 |
| Metformin Hcl | Metformin Hcl | 938 | 243 |
| Jardiance | Empagliflozin | 681 | 124 |
| Farxiga | Dapagliflozin Propanediol | 671 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 658 | 170 |
| Synthroid | Levothyroxine Sodium | 516 | 113 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 503 | 163 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 444 | 136 |
| Losartan Potassium | Losartan Potassium | 367 | 94 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 357 | 78 |
| Humalog Kwikpen U-100 | Insulin Lispro | 355 | 94 |
| Trulicity | Dulaglutide | 275 | 48 |
| Humalog | Insulin Lispro | 255 | 54 |
| Gabapentin | Gabapentin | 246 | 49 |
| Testosterone Cypionate | Testosterone Cypionate | 219 | 32 |
| Alendronate Sodium | Alendronate Sodium | 211 | 53 |
| Lisinopril | Lisinopril | 205 | 54 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 198 | 32 |
| Methimazole | Methimazole | 192 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 56 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 190 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 187 | 48 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 171 | 34 |
| Mounjaro | Tirzepatide | 146 | 31 |
| Novolog Flexpen | Insulin Aspart | 138 | 54 |
| Glipizide | Glipizide | 135 | 37 |
| Metformin Hcl Er | Metformin Hcl | 132 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 40 |
| Tresiba Flextouch U-200 | Insulin Degludec | 116 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 30 |
| Liothyronine Sodium | Liothyronine Sodium | 109 | 32 |
| Tresiba Flextouch U-100 | Insulin Degludec | 107 | 32 |
| Hydrocortisone | Hydrocortisone | 101 | 17 |
| Rybelsus | Semaglutide | 100 | 14 |
| Fluconazole | Fluconazole | 97 | 31 |
| Tradjenta | Linagliptin | 96 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 96 | 38 |
| Glipizide Er | Glipizide | 90 | 15 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 86 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 85 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 81 | 21 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 79 | 23 |
| Omeprazole | Omeprazole | 78 | 21 |
| Ezetimibe | Ezetimibe | 76 | 20 |
| Admelog Solostar | Insulin Lispro | 73 | 23 |
| Fenofibrate | Fenofibrate | 71 | 17 |
| Prednisone | Prednisone | 65 | 13 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 62 | 16 |
| Januvia | Sitagliptin Phosphate | 61 | 14 |
| Novolog | Insulin Aspart | 60 | 24 |
| Calcitriol | Calcitriol | 58 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 56 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 55 | 12 |
| Testosterone | Testosterone | 52 | 15 |
| Ramipril | Ramipril | 51 | 12 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 49 | 12 |
| Potassium Chloride | Potassium Chloride | 49 | 15 |
| Simvastatin | Simvastatin | 49 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 49 | 15 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 47 | 13 |
| Invokana | Canagliflozin | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 16 |
| Furosemide | Furosemide | 44 | 16 |
| Atenolol | Atenolol | 43 | 14 |
| Levemir Flexpen | Insulin Detemir | 43 | 22 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 11 |
| Gvoke Hypopen 2-Pack | Glucagon | 35 | 17 |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 35 | suppressed |
| Insulin Lispro | Insulin Lispro | 34 | suppressed |
| Kerendia | Finerenone | 34 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 33 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Propylthiouracil | Propylthiouracil | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 16 |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Tresiba | Insulin Degludec | 23 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | suppressed |
| Cabergoline | Cabergoline | 21 | suppressed |
| Cortef | Hydrocortisone | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 17 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Admelog | Insulin Lispro | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Teriparatide | Teriparatide | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lenvima | Lenvatinib Mesylate | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $44,509.34 · 48 records | Novo Nordisk Inc | AFREZZA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Ozempic, SYNTHROID, TEPEZZA, TWIIST | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error